SETH LERNER to Risk Assessment
This is a "connection" page, showing publications SETH LERNER has written about Risk Assessment.
Connection Strength
0.233
-
Risk Stratification of Nonmuscle Invasive Bladder Cancer and Innovative Approaches to Management of Ta Low-Grade Tumors. J Clin Oncol. 2023 01 10; 41(2):163-166.
Score: 0.108
-
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. Eur Urol. 2024 Sep; 86(3):258-264.
Score: 0.030
-
Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. Cancer Prev Res (Phila). 2017 Oct; 10(10):588-597.
Score: 0.019
-
Testis cancer--progress in risk assessment for occult retroperitoneal lymph node metastases. J Urol. 1996 Feb; 155(2):593-4.
Score: 0.017
-
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. Eur Urol. 2015 Aug; 68(2):238-53.
Score: 0.016
-
Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol. 2011 Apr; 185(4):1216-21.
Score: 0.012
-
Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. 2011 Feb; 185(2):456-61.
Score: 0.012
-
Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int. 2011 Sep; 108(5):687-92.
Score: 0.012
-
Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol. 2005 Sep 20; 23(27):6533-9.
Score: 0.008